United States Patent 8,324,225: Scope, Claim Strength, and US Patent Landscape
What does US Patent 8,324,225 claim, in plain structural terms?
US 8,324,225 is drafted around a single core scaffold, “Formula I,” with claims that broadly cover (1) the chemical compound and (2) a pharmaceutical composition. The claim set you provided is dominated by variable substituent breadth in the Formula I positions.
Claim 1: Broad “Formula I” compound coverage
Claim 1 covers:
- A is N
- R2 is hydrogen
- R3 can be very wide:
- hydrogen, hydroxyl
- C1-C3 alkyl
- C3-C8 cycloalkyl
- heterocyclyl, aryl, heteroaryl
- each of the above categories also has substituted variants (substituted by the same class scope)
- R4 is restricted but still broad:
- hydrogen
- branched C1-C5 alkyl
- branched C1-C5 alkyl substituted by phenyl
- C3-C6 cycloalkyl
- X and Y are both carbon: X is CR11 and Y is CR12
- R11 is hydrogen or C1-C3 alkyl
- R12 is BC(O)NR13R14, where:
- B is a bond, C1-C3 alkyl, or branched C1-C3 alkyl
- R13 and R14 are independently one of:
- hydrogen, C1-C3 alkyl
- C3-C8 cycloalkyl
- heterocyclyl, aryl, heteroaryl
- substituted versions of those classes
Net effect of Claim 1: the claim captures a large genus of compounds with flexible substitution at R3, R4, R11, and especially the amide-like / heteroatom-containing R12 side fragment (BC(O)NR13R14) where both R13 and R14 can independently be varied across multiple chemical classes.
Claim 2: narrows R4 to specific cycloalkyl/branched ethyl-like patterns
Claim 2 limits R4 to one of:
- C(H)(CH2CH3)2 (a branched alkyl pattern)
- C(H)(CH2CH3)Ph
- CH2CH3
- cyclopropyl, cyclopentyl, cyclohexyl
This is narrower but stays within Claim 1’s R4 definition (branched C1-C5 alkyl, phenyl-substituted branched C1-C5, and C3-C6 cycloalkyl).
Claim 3: narrows R3 to “aryl with specific substituent grammar”
Claim 3 states R3 is an aryl group that is independently substituted one or more times by:
- halogen
- C1-C4 alkoxy
- R15-amine
- R15-heterocycle
- R15-heteroaryl
Where R15 has its own structure options:
- bond
- C(O)
- N(H)C(O)
- N(H)SO2
- OC(O)
- or (CH2)1-4, optionally interrupted by O, N(CH3), or N(H)
Net effect: Claim 3 converts R3 from “any substituted aryl/heteroaryl” into “aryl specifically substituted with a defined substituent family,” which can be used to argue stronger claim focus on known SAR patterns.
Claim 4: specific aryl = phenyl
Claim 4 makes the aryl in Claim 3 explicitly phenyl.
Claim 5 and Claim 6: further substituent tightening on the phenyl ring
Claim 5 is long but functionally does this:
- It targets phenyl as R3
- The phenyl is substituted one or more times with a listed set of groups including:
- halogens and methoxy (from Claim 3 grammar)
- diethylamine
- multiple R15-labeled heterocycles/amines (piperazinyl, morpholinyl, piperidinyl, triazolyl, pyridinyl, indazolyl, pyrrolidinyl, imidazolyl, etc.)
- Those R15 substituents can themselves be further substituted with:
- C1-C4 alkyl
- C(O)C1-C4 alkyl
- S(O)2C1-C4 alkyl
- OH
- groups containing C(O)(CH2)1-3CN
- and acylated amide-like motifs N(H)C(O)C1-C4 alkyl
- R15 may be bond, C(O), N(H)C(O), N(H)SO2, OC(O), or (CH2)1-4 with optional O/N interruptions (same R15 backbone grammar)
Claim 6 further narrows:
- R3 is phenyl
- substituted with one or more of:
- N(H)C(O)aryl
- C(O)N(H)C1-C4 alkyl
- C(O)N(C1-C4 alkyl)2
- C(O)N(H)C3-C6 cycloalkyl
This positions Claim 6 as a “terminal” narrower option relative to Claim 5.
Claim 8: an alternate R4 definition with similar R12/X/Y/R3 logic
Claim 8 is a second independent version of the formula coverage (based on what you pasted). It keeps:
- A is N
- R2 is hydrogen
- R3 has the same general breadth classes (hydrogen/hydroxyl/alkyl/cycloalkyl/heterocycles/aryl/heteroaryl plus substituted forms)
- X and Y are CR11/CR12
- R11 is hydrogen or C1-C3 alkyl
- R12 is BC(O)NR13R14 with the same independent variable R13/R14 breadth
But it changes R4 to:
- branched or linear C1-C5 alkyl
- optionally interrupted or substituted with heteroatoms/halogens and additional ring systems (C3-C8 cycloalkyl, substituted cycloalkyl, heterocycle, substituted aryl/heteroaryl)
Claim 9: composition claim
Claim 9 claims:
- a pharmaceutical composition containing:
- a compound according to Claim 1 (or salt)
- plus a pharmaceutically acceptable carrier or excipient
Net effect: composition coverage is tied to the compound claim, not to a specific formulation or dose.
How broad is the genus in Claim 1 compared with Claims 3-6?
The claims create a descending scope ladder:
- Claim 1: broad genus via R3, R4, R11, and especially R12 side chain (B, R13, R14) variable classes.
- Claim 2: R4 narrowed to a fixed set of branched alkyl / ethyl / cycloalkyl exemplars.
- Claim 3: R3 restricted to aryl with substitutions drawn from a defined substituent grammar (halogen, alkoxy, and specific R15 amine/heterocycle/heteroaryl classes).
- Claim 4: aryl = phenyl.
- Claim 5: phenyl further substituted by a specific enumerated group set including specific heterocycles.
- Claim 6: phenyl further substituted by specific carbonyl-amide-like substitution patterns.
Scope compression summary (by control variable)
- Primary breadth lever: R3 (genus to aryl to phenyl to phenyl with specified substituents)
- Secondary breadth lever: R4 (broad in Claim 1; constrained in Claim 2; expanded in Claim 8 via linear options)
- Tertiary breadth lever: R12 fragment variables (B, R13, R14) remain broad throughout.
Practical implication for infringement and design-arounds
- If a competitor product keeps the Formula I core and chooses different R3/R4/R11/R12 substitutions outside the Claim 3-6 narrower enumerations, it may still remain inside Claim 1 unless R12 or the core positions are also engineered out.
- Because Claim 1 is broad, the “real” landmine for generic or follow-on chemistries is often whether the R12 = BC(O)NR13R14 pattern and the X/Y carbon substituent topology are matched.
What does Claim 8 add relative to Claim 1?
Claim 8 changes only the R4 clause while keeping the other variable architecture close.
- Claim 1 R4: hydrogen, branched C1-C5 alkyl, branched C1-C5 alkyl substituted by phenyl, or C3-C6 cycloalkyl.
- Claim 8 R4: branched or linear C1-C5 alkyl with optional interruption/substitution by heteroatoms, halogens, and additional ring systems.
Claim 8 likely expands the R4 design space beyond Claim 1 because it explicitly includes linear C1-C5 alkyl and allows broader heteroatom/halogen substitution and additional substituent categories on the R4 alkyl portion.
What is the patent “landscape” from this claim set alone?
With only the claim text provided and without the full bibliographic data (assignee, filing date, priority, jurisdictional family members, examiner art, and citation list), a landscape analysis must be anchored to structural scope rather than specific litigated patents.
The landscape features implied by the claims are:
1) Broad chemical genus claims (Formula I) plus dependent narrowing claims
A common consequence for enforcement is:
- If enforcement focuses on Claim 1, it threatens many analogs.
- If a party needs a narrower hook, Claims 3-6 and Claim 2 provide a fallback position tied to specific R3 and R4 substitution motifs.
- Claim 9 provides a second enforcement pathway for formulation makers.
2) The R12 “BC(O)NR13R14” motif is a central claim element
Across Claim 1 and Claim 8, the R12 fragment is consistently defined as:
- B is bond / C1-C3 alkyl / branched C1-C3 alkyl
- R12 is BC(O)NR13R14
- R13 and R14 cover hydrogen and extensive ring/alkyl classes
This suggests the key “chemical boundary” is whether an accused compound keeps:
- the carbonyl (C(O)) within the R12 fragment
- the N linking to R13 and R14
- the B-linked substitution on the carbonyl-adjacent position
3) Dependent claims encode commercially relevant SAR subsets
Claims 3-6 enumerate specific substituents and heterocycles. That is typical when:
- certain R3 phenyl substitution patterns correlate with potency/selectivity
- those patterns appear across multiple candidate molecules within the family
Claim-level strength assessment (what is easy to read, what is hard to escape)
Elements most likely to be difficult to design around
- Core architecture implied by Formula I with A = N
- X and Y both carbon atoms (X = CR11, Y = CR12)
- R2 = hydrogen
- R12 = BC(O)NR13R14 with variable R13 and R14
If a competitor alters any one of these in a meaningful way, it can exit the literal claim language. If they preserve them, they likely still need to exit by changing R3/R4 substitutions beyond what is covered.
Elements most likely to be modified for design-around
- R3 choice and substitution pattern
- R4 choice
- R11 (hydrogen vs C1-C3 alkyl)
However, because Claim 1 includes broad categories for substituted aryl/heteroaryl and broad categories for R3, changes in R3 must be substantive, not cosmetic.
What would matter in a US validity or infringement dispute (claim construction pressure points)
Even without the drawn Formula I, the text defines several construction levers that typically drive claim interpretation:
- “dashed line indicates a double bond”: geometry and tautomeric constraints may be argued.
- “substituted” scope: substituted alkyl/cycloalkyl/aryl/heteroaryl are broad, and the allowed substituent sets are not explicitly limited in the excerpt. That broadness increases literal coverage risk.
- R15 grammar: R15 includes both direct attachment (bond) and functional groups (C(O), N(H)C(O), N(H)SO2, OC(O)) plus a flexible (CH2)1-4 with interruptions by O or N. This makes dependent claims more intricate and can widen interpretation for substituted amide/heteroatom-containing linker substituents.
- independently substituted one or more times: supports multiple substitution patterns on the same aryl ring, reducing escape routes.
Key Takeaways
- Claim 1 is the dominant infringement risk: it covers a wide genus with flexible R3 and broad R12 = BC(O)NR13R14 variability (both R13 and R14 independently drawn from alkyl, cycloalkyl, heterocycles, and aryl/heteroaryl plus substituted variants).
- Claims 3-6 provide narrower “fallback” coverage by forcing R3 to aryl/phenyl with enumerated substituent families, including carbonyl-linked and sulfonamide-like substituents via the R15 grammar.
- Claim 8 expands R4 by adding linear C1-C5 alkyl and allowing more heteroatom/halogen interruptions/substitutions on R4.
- Claim 9 adds formulation coverage for compositions containing a Claim 1 compound plus standard pharmaceutically acceptable carriers.
- The main design-around target is likely the R12 fragment and core constraints (R2 = H, A = N, X/Y carbon definitions, and the carbonyl-linked R13/R14 amide-like motif). Changes confined to R3/R4 may still land inside Claim 1 due to its breadth.
FAQs
1) Which claim should be treated as the primary scope in US 8,324,225?
Claim 1. Claims 2-6 and 8 narrow specific substituent variables within the same Formula I framework, and Claim 9 depends on Claim 1 compound coverage.
2) Where is the broadest chemical flexibility concentrated?
The R12 side fragment (BC(O)NR13R14) is consistently broad across Claim 1 and Claim 8, because R13 and R14 each independently cover hydrogen plus multiple ring systems and substituted variants.
3) Does Claim 9 broaden beyond the compound genus?
No. It tracks Claim 1 by covering compositions containing a Claim 1 compound (or salt) plus carrier/excipient.
4) Does Claim 8 materially widen R4 relative to Claim 1?
Yes. Claim 8 expands R4 to include branched or linear C1-C5 alkyl with optional heteroatom/halogen interruption/substitution and additional ring-system substituent allowances.
5) If a competitor avoids the specific phenyl substitutions in Claims 4-6, is it automatically outside the patent?
Not necessarily. Avoiding Claims 4-6 still leaves Claim 1 coverage unless the competitor also exits the broader R3/R4/R12/core constraints.
References
[1] United States Patent No. 8,324,225 (claim text provided in prompt).
